Search PubMed⌕ Search

Biomedical subjects

H Ott

Publications and source records attributed to H Ott.

At least 145 records · Page 8Linked to original sources
PubMed1981

Lormetazepam - a benzodiazepine derivative without hangover effect? A double-blind study with chronic insomniacs in a general practice setting.

Lormetazepam, a new short-acting benzodiazepine, was tested multicentrally in 15 general practices. The subjects were 62 chronically sleep-disturbed patients. The first 7 days served as a placebo baseline week, the next 14 days were either lormetazepam or placebo in a randomized double-blind design, and during the last week placebo was given again to measure rebound effects. Lormetazepam was found to be an effective hypnotic that causes virtually no hangover the next morning. In this study no rebound effects could be measured. Visual analogue scales, among others, were used for the assessment of sleep characteristics.

Adult↗
PubMed1981

[The antagonistic effect of physostigmine on sedation by lormetazepam (author's transl)].

The purpose of this study was to determine the arousal effect of physostigmine after lormetazepam sedation on the human EEG. 12 male volunteers received 2 mg/kg bm lormetazepam and 30 minutes later physostigmine 2 mg preceded by atropine 1 mg. Generally an arousal effect of physostigmine could be clinically observed and more objectively demonstrated by reduced sleep stages in the vigilosomnogram (p less than 0.05). 2 volunteers did not fall asleep. 9 volunteers were awake 5-12 minutes after termination of physostigmine injection. 1 volunteer did not show any effect. Resedation and parasympathetic side effects did not occur. In earlier studies deep sleep stages after lormetazepam 1 or 2 mg/70 kg bm lasted 70 to 120 minutes. Physostigmine is recommended to counteract undesirable benzodiazepine induced sedation.

Anti-Anxiety Agents↗
PubMed1979

A double-blind study of erbium169 synoviorthesis in rheumatoid digital joints. Results after one year.

A double-blind study was made on the effectivenss of erbium169 synoviorthesis in the digital joints of 7 patients with erosive, seropositive rheumatoid arthritis. The study involved 70 joints observed over a 12-month period: 20 pairs of metacarpophalangeal joints (MCP) and 15 pairs of proximal interphalangeal joints (PIP) were injected with erbium169 in one joint and saline in the other one. All joints had radiological lesions corresponding to State I and II of the Steinbroker classification. Six months after synoviorthesis, good and excellent results were observed in 71% of the articulations treated with erbium169 and in only 40% of those injected with saline (placebo) (p less than 0.01). Good and excellent results were noted in 79% of the joints treated with the isotope after one year, compared with only 50% injected with the placebo (p less than 0.05). The beneficial effect of erbium169 synoviorthesis on the pain and inflammatory phenomena of rheumatoid digital joints is therefore proven. Occasionally the isotope causes a slight decrease in the range of movement of the treated joint.

Arthritis, Rheumatoid↗
PubMed1979

[Lormetazepam in preoperative sleeplessness. Dose dependance of the effect and comparison with 100 mg pentobarbital (author's transl)].

Lormetazepam (0.5, 1, 2, 4, 8 mg)--a new benzodiazepine--was tested versus Pentobarbital (100 mg) under double blind conditions on 240 preoperative inpatients for night-time sedative and side effects after acute oral intake. Results are based on p less than 0.05. Additionally p less than 0.125 in binomial-two-sample-tests was accepted. Lormetazepam shows dose dependent increase in hypnotic effects (e.g. reduction in sleep latency and number of awakenings, increase of total sleep duration), and side effects (e.g. dopiness, dizziness), but no relevant change in vital signs. About 0.5 mg of Lormetazepam are equivalent to 100 mg of Pentobarbital. 2 mg of Lormetazepam seem to be the optimum dose regarding the relation between hypnotic and side effects. In the view of anaesthesists Lormetazepam is preferable to Pentobarbital because of more favorable safety aspects.

Adult↗
PubMed1979

The approach of the European communities to the assessment of the carcinogenic risk of environmental chemicals, in particular, artificial colourings.

A brief outline is given of the rationale of the Environmental Research Programme of the European Economic Community and of its implementation. The major part of the programme is devoted to research on the exposure-effect relationships for mutagens and carcinogens and to the establishment of criteria. As a first step, a battery of test systems for mutagenicity screening is being established. These will be evaluated in a comparative test programme. The second part of the paper describes the specific legislative actions of the European Communities on food colourings. The historical background is given; and the criteria used by the Scientific Committee for Food for classifying and evaluating colouring matters are listed. Proposed regulatory action, on the basis of the report of the Committe, includes lists of colouring matters which are 'unacceptable', 'temporarily acceptable' and 'acceptable'.

European Union↗
PubMed1978

[Anxiety- an approach to defining terms and formulating a methodological concept for measuring anxiety states within the framework of clinical trials with anxiolytic substances (author's transl)].

A methodological concept for measuring anxiety states and changes in anxiety states in clinical studies with anxiolytic substances is presented: Effectivity should be evaluated on several levels which include emotions, objects of anxiety, psychophysiology, biochemistry, and observed behavior. This test concept is based on new knowledge from behavior psychology, learning theory, psychology of testing, psychophysiology, biochemistry, neuroendocrinology, and psychiatry. In diagrams, important mechanisms of thr origin of experimental, stress-induced and pathological anxiety states are depicted. The point is stressed that anxiety is situational and fluctuates.

Anti-Anxiety Agents↗
PubMed1978

2 (1H)-quinazolinones as novel non-acidic anti-inflammatory agents.

Chemical modification of 1-methyl-4-phenyl-2 (1H)-quinazolinone, a new lead in the area of non-steroidal anti-inflammatory agents, has led to 1-isopropyl-4-phenyl-7-methyl-2 (1H)-quinazolinone, proquazone. The overall anti-inflammatory profile of proquazone compares well with indomethacin qualitatively and quantitatively. It is particularly noteworthy that proquazone is the first potent anti-inflammatory drug of a non-acidic nature.

Animals↗
PubMed1978

The distribution of proquazone and three of its metabolites in serum and synovial fluid.

In 13 patients with hydrarthrosis of the knee, samples of synovial fluid and blood were drawn at regular intervals, following a single oral dose of 600 mg proquazone. The concentrations of the unchanged drug were measured fluorimetrically and those of its three principal, active metabolites by high pressure liquid chromatography. The absorption and distribution of proquazone and its metabolites were rapid. Measurable--in some cases considerable--concentrations were to be found in both the synovial fluid and serum as early as 30 minutes after intake. High concentrations were still present up to 7 hours after intake. Considerable variations were observed, both between patients and over time for each patient, so that only qualitative rather than quantitative kinetic conclusions could be drawn from the results. The concentrations were generally lower in the synovial fluid than in the serum, which may be ascribed to the drug's high protein binding.

Administration, Oral↗
PubMed1977

[Synoviorthesis of finger joints using erbium-169. Parameters influencing the clinical results at middle-term].

Synoviorthesis of the finger joint with erbium-169 is a beneficial therapeutic procedure which produces reduction of articular pain and swelling in 2/3 of cases. The effect is lasting and shows only slight regression during the first 24 months. However, if the rheumatoid disease is very active, or if the articular lesions are primarily erosive, the results are poorer. No correlation was found between therapeutic results and the radiological findings prior to 169E treatment. Erbium-169 reduces inflammation and leads to progressive articular fibrosis. Any chronic synovitis of interdigital joints resistant to appropriate conventional anti-inflammatory treatment may benefit from radio-synoviorthesis with erbium-169. Erbium-169 synoviorthesis is is technically easy to perform and free of side effects. It is a palliative measure which the authors consider a valuable complement to the classical treatment of rheumatoid arthritis.

Aged↗